| Identification | Back Directory | [Name]
Butanedioic acid, 1-[(4S)-4,11-diethyl-3,4,12,14-tetrahydro-9-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester | [CAS]
2170118-23-5 | [Synonyms]
Butanedioic acid, 1-[(4S)-4,11-diethyl-3,4,12,14-tetrahydro-9-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester | [Molecular Formula]
C26H24N2O8 | [MOL File]
2170118-23-5.mol | [Molecular Weight]
492.48 |
| Chemical Properties | Back Directory | [Boiling point ]
909.2±65.0 °C(Predicted) | [density ]
1.52±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
4.21±0.17(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
SN38-COOH is used for the synthesis of antibody-drug conjugates (ADCs). SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis[1][2]. | [References]
[1] Wilson Lim, et al. Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma. PLoS Negl Trop Dis. 2018 Apr 26;12(4):e0006437. DOI:10.1371/journal.pntd.0006437
[2] Wallin A, et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep. 2008 Jun;19(6):1493-8. PMID:18497955 |
|
| Company Name: |
YJ Pharma
|
| Tel: |
13962794339 13962794339; |
| Website: |
|
|